BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals today announced that the DNA plasmid-based product manufactured by VGX on behalf of Nucleonics, Inc. has entered Phase I human clinical trials in the United States and Europe for the treatment of chronic Hepatitis B virus (HBV) infection.
